Publicaciones en las que colabora con JOSÉ ANTONIO RAMOS ATANCE (153)

2019

  1. Usos medicinales del cannabis: ¿qué sabemos de sus propiedades curativas?

    Los Libros de la Catarata

2018

  1. Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system

    Biochemical Pharmacology, Vol. 157, pp. 67-84

2017

  1. Altered striatal endocannabinoid signaling in a transgenic mouse model of spinocerebellar ataxia type-3

    PLoS ONE, Vol. 12, Núm. 4

  2. Modeling Neurodegenerative Disorders for Developing Cannabinoid-Based Neuroprotective Therapies

    Methods in Enzymology (Academic Press Inc.), pp. 175-198

2016

  1. Dysregulation of the endocannabinoid signaling system in the cerebellum and brainstem in a transgenic mouse model of spinocerebellar ataxia type-3

    Neuroscience, Vol. 339, pp. 191-209

2015

  1. Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders

    Journal of Neuroimmune Pharmacology, Vol. 10, Núm. 2, pp. 233-244

2012

  1. Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects

    Neuropharmacology, Vol. 62, Núm. 7, pp. 2299-2308

2011

  1. Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease

    Journal of Neuroscience Research, Vol. 89, Núm. 9, pp. 1509-1518

  2. New serotonin 5-HT 1A receptor agonists with neuroprotective effect against ischemic cell damage

    Journal of Medicinal Chemistry, Vol. 54, Núm. 23, pp. 7986-7999

  3. Pharmacological activation/inhibition of the cannabinoid system affects alcohol withdrawal-induced neuronal hypersensitivity to excitotoxic insults

    PLoS ONE, Vol. 6, Núm. 8

  4. Prospects for cannabinoid therapies in basal ganglia disorders

    British Journal of Pharmacology, Vol. 163, Núm. 7, pp. 1365-1378

  5. Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ 9-THCV in animal models of Parkinson's disease

    British Journal of Pharmacology, Vol. 163, Núm. 7, pp. 1495-1506

2010

  1. Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders

    CNS Neuroscience and Therapeutics, Vol. 16, Núm. 3

2009

  1. Actualización sobre el potencial terapéutico de los cannabinoides

    Sociedad Española de Investigación en Cannabinoides (SEIC)

  2. Effects of a short-term exposure to alcohol in rats on FAAH enzyme and CB1 receptor in different brain areas

    Drug and Alcohol Dependence, Vol. 99, Núm. 1-3, pp. 354-358

  3. Lack of association between polymorphisms in cannabinoid receptor gene (CNR1) and fatty acid amide hydroxylase gene (FAAH) and eating disorders in a preliminary study

    Psychiatric Genetics, Vol. 19, Núm. 6, pp. 336

2008

  1. CB1 receptor blockade reduces the anxiogenic-like response and ameliorates the neurochemical imbalances associated with alcohol withdrawal in rats

    Neuropharmacology, Vol. 54, Núm. 6, pp. 976-988

  2. Role of CB2 receptors in neuroprotective effects of cannabinoids

    Molecular and Cellular Endocrinology, Vol. 286, Núm. 1-2 SUPPL. 1

2007

  1. An overview on the biochemistry of the cannabinoid system

    Molecular Neurobiology, Vol. 36, Núm. 1, pp. 3-14

  2. Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors

    European Journal of Neuroscience, Vol. 26, Núm. 4, pp. 843-851